NEK2与前列腺癌预后的相关研究

doi:10.3969/j.issn.1000-8535.2017.02.001

摘要/Abstract

摘要： 目的研究NEK2(中心体相关激酶2)在前列腺癌和良性组织中的表达情况及其与前列腺癌预后的相关性。方法运用qRT-PCR检测NEK2在前列腺癌和癌旁组织的表达差异,通过组织芯片免疫组化染色检测的方法检验NEK2在前列腺癌和癌旁组织的表达情况,最后使用Taylor的数据对NEK2进行生物信息学分析。结果 qRT-PCR检测NEK2在前列腺癌组织的表达显著高于癌旁组织(6.93±0.15 vs 5.38±0.4,t=6.25,P=0.003),组织芯片免疫组化结果显示NEK2在前列腺癌组织的表达显著高于癌旁组织(5.84±0.56 vs 4.27±0.49,t=5.38, P<0.001),结合Taylor公用数据库分析,NEK2高表达组患者术后的生化复发生存率减少( χ²=4.33,P=0.037),NEK2高表达组和低表达组在前列腺癌总体生存率上没有明显区别( χ²=0.27,P=0.605)。结论 NEK2参与前列腺癌的发生、发展进程,同前列腺癌发病进程密切相关,通过检测前列腺癌患者NEK2的表达情况,可早期预测生化复发的概率,能够作为判断前列腺癌预后的潜在生物学标志物。

关键词: 前列腺癌, NEK2, 生化复发, 预后

Abstract: Objective To investigate the expression of NEK2(NIMA-related kinase 2)in prostate cancer as well as benign prostatic hyperplasia,and the involvement of NEK2 in the prognosis of prostate caner(PCa). Methods The different expression of NEK2 in the tissue of prostate cancer and the adjacent benign tissues of prostate were measured by real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohositochemistry analysis,and then bioinformatically analyzed using the Taylor dataset. Results QRT-PCR showed that NEK2 was highly expressed in PCa than in the adjacent benign tissues (6.93±0.15 vs 5.38±0.4,t=6.25,P=0.003). Immunohositochemistry analysis showed the expression of NEK2 was higher in PCa than in the adjacent benign tissues(5.84±0.56 vs 4.27±0.49,t=5.38, P<0.001). Furthermore, the biochemical recurrence-free time of PCa patients in high NEK2 expression groups significantly reduced( χ²=4.33,P=0.037). The overall survival time of PCa patients was not correlated to NEK2 expression levels( χ²=0.27,P=0.605). Conclusion The above findings suggest that NEK2 is associated with production and development of PCa, and also critically connected with the process of PCa,which indicate that we can predict the probability of the biochemical recurrence-free time by detecting the expression of NEK2 in PCa patients,and NEK2 can also become a potential biomarker for PCa prognosis.

Key words: Prostate cancer, NEK2, Biochemical recurrence, Prognosis

赵海波, 吴永定, 曾彦茹, 杨盛帮, 李博伟, 梁宇翔. NEK2与前列腺癌预后的相关研究[J]. 广州医药, 2017, 48(2): 1-5.

ZHAO Haibo, WU Yongding, ZENG Yanru, YANG Shengbang, LI Bowei, LIANG Yuxiang. The relevant research between NEK2 and the prognosis about prostate cancer[J]. Guangzhou Medical Journal, 2017, 48(2): 1-5.

参考文献

[1] SIEGEL R L, MILLER K D, JEMAL A, et al. Cancer statistics, 2015[J]. CA Cancer J Clin,2015, 65(1):5-29.
[2] DEMARZO A M, NELSON W G, ISAACS W B, et al. Pathological and molecular aspects of prostate cancer[J]. Lancet,2003, 361(9361):955-964.
[3] HUMPHREY P A. Diagnosis of adenocarcinoma in prostate needle biopsy tissue[J]. J Clin Pathol,2007, 60(1): 35-42.
[4] ALBERTSEN P C.PSA and the conservative treatment of early prostate cancer[J]. Arch Ital Urol Androl,2006, 78(4): 152-153.
[5] PARKIN D M, BRAY F, FERLAY J,et al.Global cancer statistic,2012[J]. CA Cancer J Clin,2005, 55(2):74-108.
[6] SZPONAR A, ZUBAKOV D, PAWLAK J,et al. Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatalprogression[J]. Int J Cancer,2009, 124(9):2071-2076.
[7] KOKURYO T, SENGA T, YOKOYAMA Y,et al. NEK2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination ofcholangiocarcinoma[J]. Cancer Res,2007, 67(20):9637-9642.
[8] WANG S, LI W, LV S, et al. Abnormal expression of NEK2 and β-catenin in breast carcinoma: clinicopathological correlations[J]. Histopathology,2011, 59(4):631-642.
[9] HAYWARD D G, CLARKE R B, FARAGHER A J,et al. The centrosomal kinase NEK2 displays elevated levels of protein expression in human breast cancer[J]. Cancer Res,2014, 64(20):7370-7376.
[10] YIN M, BASTACKY S, CHANDRAN U,et al. Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors[J]. J Urol,2008, 179(3):892-895.
[11] HUANG Y Q, HAN Z D, LIANG Y X,et al. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer[J]. Med Oncol,2014, 31(1):820.
[12] SONN S, JEONG Y, RHEE K. Nip2/centrobin may be a substrate of NEK2 that is required for proper spindle assembly during mitosis in earlymouse embryos[J]. Mol Reprod Dev,2009, 76(6):587-592.
[13] VOS S, HOFMANN W K, GROGAN T M,et al. Gene expression profile of serial samples of transformed B-cell lymphomas[J]. Lab Invest,2003, 83(2): 271-285.
[14] ZHOU W, YANG Y, XIA J,et al.NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers[J]. Cancer Cell,2013, 23(1):48-62.

[1]	肖驰, 周雪, 徐丹, 杨美英, 费晶, 巩平. SNCG在卵巢癌中的表达及其临床意义[J]. 广州医药, 2021, 52(5): 1-7.
[2]	张林洋, 朱玲玲, 朱国华. 中医药治疗前列腺癌研究进展[J]. 广州医药, 2021, 52(5): 135-138.
[3]	古嘉基, 连泳欣, 丘福满. m6A甲基化基因风险评估模型在卵巢癌预后的临床意义[J]. 广州医药, 2021, 52(3): 1-8.
[4]	谢艳林, 董燕, 柳建华. 经胸超声心动图在Stanford A型主动脉夹层的诊断及预后评估中的价值[J]. 广州医药, 2021, 52(3): 36-40.
[5]	罗水妹, 黄颂平, 许白兰, 沈冰寒. 肺癌并发肺栓塞的危险因素及预后分析[J]. 广州医药, 2021, 52(2): 40-45.
[6]	岑昕贝, 凌济忠, 万跃平, 万颂, 华伟, 江敏耀, 习明. NR3C1表达与前列腺癌生化复发的相关性研究[J]. 广州医药, 2020, 51(4): 22-27.
[7]	刘霞, 方喜生, 翁成荫, 伍勇, 毛海波, 李宝秀, 王丽娜, 刘国龙. 原发性肝癌患者循环肿瘤细胞检测及其与术后复发转移的关系[J]. 广州医药, 2020, 51(2): 36-39.
[8]	李赟, 李勇, 巩平, 李小英, 李娜. 中性粒细胞与淋巴细胞比值在晚期不可切除结直肠癌患者化疗疗效及预后的意义[J]. 广州医药, 2020, 51(1): 59-65.
[9]	张春燕, 张赐理. 幽门螺杆菌感染与儿童过敏性紫癜患病及预后的相关性研究[J]. 广州医药, 2018, 49(4): 79-81.
[10]	曾维威, 谢克基, 韦兴华, 莫灿程, 汤平. 17年间前列腺癌的临床特征变化[J]. 广州医药, 2018, 49(3): 5-9.
[11]	缪智雄, 朱旭生. ⁹⁹锝-亚甲基二膦酸盐治疗前列腺癌骨转移疗效观察[J]. 广州医药, 2018, 49(3): 94-96.
[12]	钟思苗, 陈瑞芳, 苏建平, 邹绮嫦, 吴小文. 不同分化程度前列腺癌经直肠超声图像特征观察[J]. 广州医药, 2018, 49(3): 103-105.
[13]	李冠博. 控制性减压术对重型颅脑损伤患者神经功能、颅内压及预后的影响[J]. 广州医药, 2018, 49(2): 114-116.
[14]	陈佳鸿, 方树敏, 梁应科, 刘泽贞, 朱学进, 蔡周达, 董卫民, 钟惟德. PBK在前列腺癌组织中的表达及临床意义[J]. 广州医药, 2017, 48(4): 1-6.
[15]	刘丽, 魏莲, 袁利, 王立辉, 易艳妮. 长链非编码RNA LINC00672与肺癌预后的关联研究[J]. 广州医药, 2017, 48(4): 7-11.